Primary Biliary Cholangitis clinical trials at UCSF
2 in progress, 1 open to eligible people
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
open to eligible people ages 18-80
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
San Francisco, California and other locations
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Sorry, in progress, not accepting new patients
To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo
San Francisco, California and other locations
Our lead scientists for Primary Biliary Cholangitis research studies include Monika Sarkar.
Last updated: